PCSK9 inhibitors do not increase the risk of diabetes (RR 0.99; 95% CI: 0.92–1.07) and same was true for ezetimibe (RR 1.05; 95% CI: 0.95–1.15). The gene discussed is PCSK9; the disease is diabetes mellitus.